Navigation Links
Catalyst Pharmaceutical Partners Begins Enrollment for Its U.S. Phase II Clinical Trial of CPP-109 in Patients with Cocaine Addiction
Date:1/25/2008

ric acid (GABA), a dopamine-modulating neurotransmitter. The resulting excess GABA suppresses the increase in dopamine release caused by cocaine. All addictive drugs elevate dopamine levels in the parts of the brain associated with reward and reinforcement. It is thought that this reinforcing effect is the primary biochemical explanation for addiction. CPP-109 indirectly keeps dopamine levels in the normal range without impairing normal dopamine-based mechanisms. It is also thought that this effect may reduce craving, an effect in addicts which makes it very difficult for them to stop their drug habit.

About Catalyst Pharmaceutical Partners

Catalyst Pharmaceutical Partners, Inc. is a biopharmaceutical company focused on the development and commercialization of prescription drugs for the treatment of addiction. The Company has obtained from Brookhaven National Laboratory an exclusive worldwide license for nine patents and four patents pending in the United States relating to the right to use vigabatrin to treat a wide variety of substance addictions and obsessive-compulsive disorders. Catalyst has also been granted rights to Brookhaven's vigabatrin-related foreign patents or patents pending in more than 30 countries.

The Company's initial product candidate is CPP-109, also known as vigabatrin. CPP-109 has been granted "Fast Track" status by the FDA for the treatment of cocaine addiction. This indicates that the FDA has recognized that CPP-109 is intended for the treatment of a serious or life-threatening condition for which there is no effective treatment and which demonstrates the potential to address unmet medical needs. CPP-109 was selected as one of the five most promising drugs entering Phase II trials in the July-September 2007 issue of The Ones To Watch, published by Thomson Scientific, a Thomson Corporation publication.

This press release contains forward-looking statements. Forward-looking statements involve known and unknown risk
'/>"/>

SOURCE Catalyst Pharmaceutical Partners, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Peregrine Pharmaceuticals Receives Approval to Conduct a Second Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer
2. Peregrine Pharmaceuticals Receives Approval to Conduct a Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer
3. Cogentus Pharmaceuticals Begins Clinical Study to Confirm the Full Antiplatelet Benefit of New Combination Medicine CGT-2168
4. Cerimon Pharmaceuticals Initiates Phase II/III Clinical Studies to Evaluate its Diclofenac Patch for Mild to Moderate Pain
5. Morria Biopharmaceuticals Plc Announces Preliminary Safety and Tolerability Results From Its Phase I Clinical Study of MRX-4 in Allergic Rhinitis Patients
6. First Patient Enrolled in Cogentus Pharmaceuticals Pivotal Phase 3 Trial of Novel Combination Medicine
7. Arena Pharmaceuticals Announces Positive Phase 1a Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis and Initiates Phase 1b Clinical Trial
8. Vion Pharmaceuticals Announces FDA Lift of Clinical Hold on Phase III Study of Cloretazine(R) (VNP40101M) and Cytarabine in Relapsed AML
9. Arena Pharmaceuticals Announces APD668 Initial Clinical Study Results Suggest Glucose-Dependent Insulinotropic Receptors May Improve Glucose Control in Patients With Type 2 Diabetes
10. Fovea Pharmaceuticals Receives Orphan Drug Designation from EC for RdCVF for the Treatment of Retinitis Pigmentosa
11. VIA Pharmaceuticals Enrolls First Patient in Phase 2 Clinical Trial to Measure Impact of VIA-2291 to Reduce Vascular Inflammation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... May 22, 2015 Research and Markets ... of the "Latest Regulations on Pharmaceutical International ... their offering. This is first time ... guidance on international multi-center clinical trials of drugs ... begun to be implemented on March 1, 2015. ...
(Date:5/22/2015)... , May 22, 2015 AcelRx Pharmaceuticals, ... focused on the development and commercialization of innovative therapies ... announced that interim chief executive officer Howie Rosen ... and chief financial officer Tim Morris will ... of the two presentations are as follows: ...
(Date:5/21/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/jx648d/north_american ... "North American Active Wound Care Market by Method ... Ulcer), by End-User (In-Patient, & Out-Paient) - Analysis ... offering. ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,The North American ... at a CAGR of 3.1% from 2014 to ...
Breaking Medicine Technology:2015 Regulations on Pharmaceutical International Multi-Center Clinical Trials in China 2AcelRx Pharmaceuticals to Present at Two Upcoming Investor Conferences In June 2North American Active Wound Care Market 2015-2019 with Smith and Nephew, Molyncke HealthCare & ConvaTec Dominating 2
... Inc., today announced Phase 2b trial results for its ... levels by 30 to 40 percent in patients whose ... The study included an arm combining DCCR with fenofibrate ... arm, DCCR was shown to be additive to fenofibrate ...
... iBio, Inc. (NYSE AMEX: IBIO) today announced ... iBio,s proprietary fusion-protein technology in combination with influenza virus ... use of lichenase in an adjuvant-like role to improve ... the Fraunhofer USA Center for Molecular Biotechnology (FhCMB), iBio,s ...
Cached Medicine Technology:Phase 2b Trial Shows Unique Lipid Efficacy Profile of Novel Compound to Reduce Elevated Triglyceride Levels 2Phase 2b Trial Shows Unique Lipid Efficacy Profile of Novel Compound to Reduce Elevated Triglyceride Levels 3Patent Issued on Fusion-Protein Vaccine Technology 2Patent Issued on Fusion-Protein Vaccine Technology 3
(Date:5/26/2015)... Dearborn Ear, Nose & Throat in Dearborn, ... new and improved website to better showcase their Detroit ... Ear, Nose & Throat’s new website utilizes an innovative ... website seamlessly on any desktop computer, tablet or mobile ... Ear, Nose & Throat website include an innovative ...
(Date:5/25/2015)... May 26, 2015 The report ... comprehensive information on the therapeutic development for Liver ... new targets and MOAs to produce first-in-class and ... review of Liver Failure with 22 market data ... is available at http://www.rnrmarketresearch.com/liver-failure-pipeline-review-h1-2015-market-report.html . , ...
(Date:5/25/2015)... Author Vincent N. Cefalu, Sr., MD. has always believed ... many of them aren’t aware of many products that are ... don’t realize the dangers of physical inactivity and the many ... that exist. There is also the fact that smokers ... , In “ A Doctor’s Prescription for Longevity and Survival ...
(Date:5/25/2015)... 2015 The National Association of ... 2015-2016 inductee into its VIP Professional Woman of the ... for leadership in dentistry. NAPW is the nation's leading ... 700,000 members and over 200 operating local chapters. ... group of professional women,” said NAPW President Star Jones. ...
(Date:5/25/2015)... 2015 The National Association of ... as a 2015-2016 inductee into its VIP Woman ... prestigious distinction for leadership in biomedical engineering. NAPW is ... boasting more than 700,000 members and over 200 operating ... this exceptional group of professional women," said NAPW President ...
Breaking Medicine News(10 mins):Health News:Dearborn Ear, Nose & Throat Launches ‘Responsive Design’ Website 2Health News:Liver Failure Pipeline Assessment and Key Players Review H1 2015 Market Research Report Available at RnRMarketResearch.com 2Health News:Liver Failure Pipeline Assessment and Key Players Review H1 2015 Market Research Report Available at RnRMarketResearch.com 3Health News:Liver Failure Pipeline Assessment and Key Players Review H1 2015 Market Research Report Available at RnRMarketResearch.com 4Health News:New Book Reveals ‘A Doctor’s Prescription for Longevity and Survival’ 2Health News:New Book Reveals ‘A Doctor’s Prescription for Longevity and Survival’ 3Health News:National Association of Professional Women Inducts Dr. Laquinas Hooked, D.D.S. of General Dentist, Into its VIP Professional Woman of the Year Circle 2Health News:National Association of Professional Women Inducts Lisa Ferrara, Ph.D., CEO of OrthoKinetic Technologies, Into its VIP Professional Woman of the Year Circle 2
... genetic mutation that improves response to therapy , , WEDNESDAY, ... inhibits tumor blood vessel formation slows the progression of ... finds. , Of the 93 patients with rapidly progressing ... motesanib diphosphate. Of those 49 patients, 14 percent had ...
... Compact, bedside brain-activity monitors detected most seizures in ... Medicine in St. Louis showed. That means the ... electrical seizures until confirmation with conventional EEG (electroencephalography), ... the June issue of Pediatrics . ...
... CEO, American Association of,Homes and Services for the ... Exceptions Process, WASHINGTON, July 2 Following ... American Association of Homes and,Services for the Aging, ... Process:, "Medicare beneficiaries are once again having ...
... that its President and Chief Executive Officer Sean ... Year(R) 2008 Award in the,Applied Science category in ... region. This award recognizes outstanding entrepreneurs who,are building ... an independent panel of judges and the award ...
... (THURSDAY) 10:00 A.M., WASHINGTON, July 2 Food ... regulation that would require,growers and packers of fruits and ... those products to be traced back to their farm,of ... will reiterate its,call for growers to implement written food ...
... David Belkin died,last February during a pick-up basketball game, but ... tell about it., On Sunday, July 6 at 11 ... with the Sudden Cardiac Arrest (SCA) Foundation,s,People Saving People Award ... Rd. (behind Wayne Memorial Hospital) in Honesdale., Also invited ...
Cached Medicine News:Health News:New Drug Slows Thyroid Cancer 2Health News:Seizures in newborns can be detected with small, portable brain activity monitors 2Health News:Seizures in newborns can be detected with small, portable brain activity monitors 3Health News:AAHSA Statement: Therapy Caps Ration Care 2Health News:Precision Therapeutics President and CEO Sean McDonald Named Ernst & Young Entrepreneur of the Year(R) 2008 Regional Award Winner 2Health News:Back From the Dead: Cardiac Arrest Victim Salutes His Rescuer 2
... grafting or creation of a vascular access, ... is of the utmost importance in many ... for those seeking a high-precision tunneling instrument. ... risk of twisting or kinking for more ...
... Cardiovascular Patch utilizes advanced fluoropolymer ... around penetrating suture and decrease ... much as 88 percent. This ... retention, multi-directional strength and low ...
... have met the challenges of the ... exceptional performance and quality, they have ... worldwide. These grafts require no preclotting, ... infection, and ensure utmost thrombectomy safety. ...
... GORE-TEX Stretch Vascular Grafts have met ... vascular procedures. Recognized for exceptional performance ... endorsement of renowned surgeons worldwide. These ... and the spread of infection, and ...
Medicine Products: